Results 111 to 120 of about 24,904,492 (241)

Molecular Editing Reveals a Bilobalide Chemotype that Attenuates Prolyl Endopeptidase (PREP)‐Linked Neuroinflammation

open access: yesAdvanced Science, EarlyView.
Molecular editing of bilobalide uncovers BB56, a PREP‐engaging chemotype with enhanced anti‐inflammatory activity in microglia. Integrated CETSA‐MS, SAR, and pathway analyses link BB56 to attenuation of p38 MAPK/NF‐κB and NLRP3‐associated inflammatory signaling, highlighting bilobalide editing as a strategy for developing neuroinflammation‐modulating ...
Chanin Sillapachaiyaporn   +20 more
wiley   +1 more source

Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors. [PDF]

open access: yesJ Leukoc Biol, 2021
Jøntvedt Jørgensen M   +6 more
europepmc   +1 more source

Stage‐Adaptive Janus Microneedle System for Redox‐Immune Regulation and Mitochondrial Protection in Infected Diabetic Wound Healing

open access: yesAdvanced Science, EarlyView.
ABSTRACT Infected diabetic wounds are sustained by a vicious cycle of hyperglycemia‐driven bacterial infection, persistent oxidative stress, and excessive inflammation, which collectively disrupt the ordered progression of tissue repair. Here, we engineered a stage‐adaptive Janus microneedle patch (MN‐FeSAC‐PPE) to enable a staged therapeutic process ...
Mengting Yin   +13 more
wiley   +1 more source

Novel Selective Cyclooxygenase-2 Inhibitors Designed by Molecular Dynamic Simulation and Virtual Screening

open access: yes, 2009
[[abstract]]Cyclooxygenase (COX) had been reported in several studies that it related to carcinogenesis, especially the cyclooxygenase-2 (COX-2) because it could increase new blood vessel formation and proliferation affecting the development of cancer ...
tseng you jen
core  

Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors

open access: yesJournal of Experimental Pharmacology, 2012
Randall E Harris,1 Joanne Beebe,1 Galal A Alshafie21College of Medicine and College of Public Health, 2College of Pharmacy, The Ohio State University, Columbus, Ohio, USAAbstract: We conducted a series of epidemiologic studies to evaluate the ...
Harris RE, Beebe J, Alshafie GA
doaj  

Rapid In Vitro Pathological Diagnosis of Glioma Using Dual‐Color Quantum Dot Probes for Precise Intraoperative Resection

open access: yesAdvanced Science, EarlyView.
Glioma resection surgery is challenging because of the infiltrative growth of the tumor into nearby tissue and the different surgical requirements for gliomas with different mutation types. To improve the precision and effectiveness of glioma resection, this study developed a new imaging probe that enables the tumor boundary and mutation status to be ...
Dongdong Wu   +12 more
wiley   +1 more source

Cyclooxygenase-2 in prostate cancer

open access: yes, 2000
Prostate cancer (pc) is the most commonly diagnosed adenocarcinoma and the second leading cause of cancer death after lung cancer in men in the Western world.
Madaan, S., Lalani, E-N., Abel, P. D.
core  

Inhibitors of cyclooxygenase-2-dependent modulation of functional characteristics of leukocytes

open access: yesRUDN Journal of Medicine, 2009
Cyclooxygenase (COX), the primary enzyme responsible for the synthesis of prostanoids, exists in at least 2 isoforms. COX-2 has been suggested to be the isoform primarily responsible for synthesis of prostaglandins (PGs) in the context of inflammation ...
A V Pasechnik   +2 more
doaj  

EpCAM+ Extracellular Vesicle PD‐L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response

open access: yesAdvanced Science, EarlyView.
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Byeonggeol Mun   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy